Target Price | $125.88 |
Price | $105.89 |
Potential |
18.87%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Ligand Pharmaceuticals Incorporated 2025 .
The average Ligand Pharmaceuticals Incorporated target price is $125.88.
This is
18.87%
register free of charge
$144.00
35.99%
register free of charge
$110.00
3.88%
register free of charge
|
|
A rating was issued by 7 analysts: 7 Analysts recommend Ligand Pharmaceuticals Incorporated to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Ligand Pharmaceuticals Incorporated stock has an average upside potential 2025 of
18.87%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 131.31 | 156.29 |
33.09% | 19.02% | |
EBITDA Margin | 35.97% | 43.18% |
25.53% | 20.05% | |
Net Margin | 40.53% | 39.28% |
321.92% | 3.07% |
7 Analysts have issued a sales forecast Ligand Pharmaceuticals Incorporated 2024 . The average Ligand Pharmaceuticals Incorporated sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Ligand Pharmaceuticals Incorporated EBITDA forecast 2024. The average Ligand Pharmaceuticals Incorporated EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Ligand Pharmaceuticals Incorporated Analysts have issued a net profit forecast 2024. The average Ligand Pharmaceuticals Incorporated net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.94 | 3.39 |
248.48% | 15.31% | |
P/E | 31.22 | |
EV/Sales | 10.97 |
5 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast for earnings per share. The average Ligand Pharmaceuticals Incorporated <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Ligand Pharmaceuticals Incorporated stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Ligand Pharmaceuticals Incorporated...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.